304 filings
Page 12 of 16
6-K
7kzbikl8 ithu
29 Aug 14
Current report (foreign)
12:00am
6-K
obcpjc3kx3zop tjp1
13 Aug 14
Current report (foreign)
12:00am
SC 13G
9yvtwa6dht1o01
8 Aug 14
GW Pharmaceuticals PLC
12:00am
6-K
b6do53
6 Aug 14
GW Pharmaceuticals plc Reports 2014 Third Quarter Financial Results
12:00am
6-K
d2nv9mqmt4q3a2i 2w7
26 Jun 14
Current report (foreign)
12:00am
6-K
b4pmz2u0isu06hx6gcz
20 Jun 14
GW Pharmaceuticals plc Announces Pricing of U.S. Public Offering of ADSs Totalling Approximately $148 Million on NASDAQ Global Market
12:00am
424B5
g94ncqospgk4nvte0
20 Jun 14
Prospectus supplement for primary offering
12:00am
FWP
011kf645uq 1xo8
19 Jun 14
Free writing prospectus
12:00am
6-K
557pgu57
18 Jun 14
GW Pharmaceuticals Announces Proposed Public Offering of ADSs
12:00am
424B5
i4sql 4o3
17 Jun 14
Prospectus supplement for primary offering
12:00am
6-K
8hfsxm4j
17 Jun 14
Current report (foreign)
12:00am
6-K
y18ckwvq03m15je 00p
9 Jun 14
GW Pharmaceuticals Announces Epidiolex® Receives Fast Track Designation from FDA for the Treatment of Dravet Syndrome
12:00am
F-3ASR
uofe9zq
7 May 14
Automatic shelf registration (foreign)
12:00am
6-K
w3m nqqsuie
7 May 14
GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2/3 Clinical Trial of Epidiolex® in the Treatment of Dravet Syndrome
12:00am
6-K
ao786hsd2ve1uv3
17 Mar 14
GW Pharmaceuticals Provides Update on Cannabinoid Pipeline
12:00am
6-K
ev92p7
12 Mar 14
Current report (foreign)
12:00am
6-K
0gqd b37d
28 Feb 14
GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex® in the Treatment of Lennox-Gastaut Syndrome
12:00am
SC 13G
e48hnytsbal741
13 Feb 14
GW Pharmaceuticals PLC
12:00am
6-K
8ks082ynpm5v3zacf33w
5 Feb 14
GW Pharmaceuticals plc Reports First Quarter 2014 Financial Results and Operational Progress
12:00am
6-K
uyg8ru8dq6x6d
16 Jan 14
Current report (foreign)
12:00am